- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07612709
Unilateral Ventilation on Cardiopulmonary Bypass During Cardiac Surgery
24 mei 2026 bijgewerkt door: Dr. Martin Dworschak, Medical University of Vienna
Unilateral Ventilation on Cardiopulmonary Bypass During Cardiac Surgery in Patients at Increased Risk for Severe Postoperative Pulmonary Complications
This study investigates if single lung ventilation on cardiopulmonary bypass can mitigate postoperative lung water accumulation determined by lung ultrasound in the ventilated lung as compared to the non-ventilated lung in patients at high-risk for developing severe pulmonary complications after cardiac surgery.
Studie Overzicht
Toestand
Nog niet aan het werven
Conditie
- Cardiopulmonale bypass
- Long echografie
- Elektrische impedantietomografie (EIT)
- Enkelvoudige longventilatie
- Longbeschermende ventilatie
- Longwaterbeoordeling
- Long-compliantie
- X-thorax voor klinische evaluatie
- Longcomplicaties bij chirurgische patiënten
- Biomarkers van vasculair endotheliaal letsel
- Oxygenatie-indices
- Cardiale patiënten met een hoog risico
Interventie / Behandeling
Studietype
Ingrijpend
Inschrijving (Geschat)
45
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studiecontact
- Naam: Martin Dworschak, MD, MBA
- Telefoonnummer: 41090 +43-1-40400
- E-mail: martin.dworschak@meduniwien.ac.at
Studie Contact Back-up
- Naam: Edda M. Tschernko, MD, MBA
- Telefoonnummer: 41060 +43-1-40400
- E-mail: edda.tschernko@meduniwien.ac.at
Studie Locaties
-
-
State of Vienna
-
Vienna, State of Vienna, Oostenrijk, 1090
- General hospital Vienna
-
Contact:
- Martin Dworschak, MD, MBA
- Telefoonnummer: 41090 +43-1-40400
- E-mail: martin.dworschak@meduniwien.ac.at
-
Contact:
- Edda M. Tschernko, MD, MBA
- Telefoonnummer: 41060 +43-1-40400
- E-mail: edda.tschernko@meduniwien.ac.at
-
Hoofdonderzoeker:
- Martin Dworschak, MD, MBA
-
Onderonderzoeker:
- Edda M. Tschernko, MD, MBA
-
Onderonderzoeker:
- Keso Skhirtladze-Dworschak, MD
-
Onderonderzoeker:
- Florentina Zingher, MD
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Oudere volwassene
Accepteert gezonde vrijwilligers
Nee
Beschrijving
Inclusion Criteria:
- Patients at increased risk for postoperative pulmonary complications
- Major elective cardiac surgery
- Prolonged duration of cardiopulmonary bypass
- Patients older than 65 years of age
- Informed consent
Exclusion Criteria:
- Emergency
- Urgent procedures
- Patients with implanted pacemakers
- Patients with internal cardioverter/defibrillators
- Decompensated cardiac disease
- Pulmonary disease
- Recent pneumonia
- Need for temporary perioperative mechanical support
- Patients not willing to participate
- Treatment with inhaled nitric oxide
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Risk group
Lung ventilated during cardiopulmonary bypass using single-lung ventilation via double-lumen tube.
|
This lung will be ventilated during cardiopulmonary bypass using volume-controlled ventilation with a tidal volume of 3 mL/kg ideal body weight, a PEEP of 5 cmH2O, a respiratory rate of 10/min, and a fraction of inspired oxygen of 30%.
The contralateral lung will not be ventilated during cardiopulmonary bypass and will be allowed to collapse.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Lung aeration score of both lungs.
Tijdsspanne: Lung ultrasound investigations will be performed at baseline, i.e., before surgery, on the day of surgery, and on day 1 and 2 after surgery in the intensive care unit.
|
The aeration score of each lung is the sum of the aeration scores determined in each of six lung quadrants in each lung, which can range from 0 (normal ventilation) to 3 (atelectasis/consolidation).
|
Lung ultrasound investigations will be performed at baseline, i.e., before surgery, on the day of surgery, and on day 1 and 2 after surgery in the intensive care unit.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Radiologic assessment of Kerley B lines as indicators of lung edema.
Tijdsspanne: Performed on the day of surgery and on day 1 and 2 after surgery on the intensive care unit.
|
Number of Kerley B lines in both lungs determined by chest x-ray where stage 1 (no Kerley B lines) reflects best outcome, stage 2 (Kerley B lines become visible) indicates interstitial edema, and stage 3 (increased number of Kerley B lines also in non-dependent areas and partially obscured in dependent parts of the lung) are a sign of alveolar edema.
|
Performed on the day of surgery and on day 1 and 2 after surgery on the intensive care unit.
|
|
Presence of pleural effusion in chest x-ray.
Tijdsspanne: Performed on the day of surgery and on day 1 and 2 after surgery on the intensive care unit.
|
Severity assessment will be semi-quantitative with 0 = no effusion, 1 = small effusion (with blunting of the basal lung segments and the costophrenic angle), 2 = moderate effusion (fluid extents to the mid-hemithorax creating a "meniscus sign"), and 3 = massive effusion (the whole lung appears opaque with displacement of the heart to the contralateral side if located unilaterally).
|
Performed on the day of surgery and on day 1 and 2 after surgery on the intensive care unit.
|
|
Determination of the Global Inhomogeneity (GI) index in both lungs separately by thoracic Electrical Impedance Tomography (EIT).
Tijdsspanne: On the day of surgery and on day 1 and 2 after surgery in the intensive care unit.
|
Global inhomogeneity is calculated as the sum of the absolute differences between the median value of tidal variation and every single pixel value, divided by the sum of all impedance values, to normalize the calculated values.
A GI index closer to 0 represents highly homogeneous (even) ventilation.
Higher values (i.e., > 0.5) indicate that some parts of the lung are over-distended while others are poorly aerated or collapsed (atelectasis).
|
On the day of surgery and on day 1 and 2 after surgery in the intensive care unit.
|
|
Worst oxygenation (Horowitz) index measured per day during routine blood gas checks.
Tijdsspanne: Assessed on the day of surgery and on day 1 and 2 after surgery.
|
The Horowitz index (HI) is calculated by diving arterial oxygen partial pressure determined in the blood gas by the fraction of inspired oxygen.
It will be assessed after each blood gas check and the lowest HI during one day will be entered for further statistical analysis.
The degree of impaired lung function will be determined as follows: HI > 300 mmHg (healthy lung function), HI between 201-300 mmHg (mild lung injury), HI between 101-200 mmHg (moderately severely impaired lung function), and HI < 100 mmHg (severe lung injury, ARDS).
|
Assessed on the day of surgery and on day 1 and 2 after surgery.
|
|
Static lung compliance determined in each lung separately.
Tijdsspanne: On the day of surgery in the operating room before and after cardiac surgery on cardiopulmonary bypass when the patient is still ventilated via double lumen tube.
|
Static lung compliance of the ventilated and the non-ventilated lung will be determined twice for each patient.
Static compliance in healthy adults ranges between 60 and 100 mL/cm H₂O.
Values below 50 mL/cm H₂O would be considered abnormally low.
|
On the day of surgery in the operating room before and after cardiac surgery on cardiopulmonary bypass when the patient is still ventilated via double lumen tube.
|
|
Amount of released immune modulators.
Tijdsspanne: Determined on the day of surgery as well as on day 1, 2, 3, and 4 after surgery.
|
Serum levels for HSP70, MMP-8, MMP-9, TIMP-1, and Lipocalin-2 will be determined in patients' blood samples, with normal values ranging from 0.2-3 ng/mL for HSP70, 0.3-1.2
ng/mL for MMP-8, 14-100 ng/mL for MMP-9, 80-150 ng/mL for TIMP-1, and 20-130 ng/mL for Lipocalin-2, respectively.
|
Determined on the day of surgery as well as on day 1, 2, 3, and 4 after surgery.
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Length of ICU and hospital stay.
Tijdsspanne: These variables will be censored at study completion, on average 30 days.
|
The duration from transfer to the intensive care unit until discharge to a step-down unit and the duration of hospitalization of the patient will be determined in days.
|
These variables will be censored at study completion, on average 30 days.
|
|
In-hospital mortality.
Tijdsspanne: In-hospital mortality will be censored at study completion, on average 30 days.
|
It will be recorded if the patient has been discharged from the hospital alive.
|
In-hospital mortality will be censored at study completion, on average 30 days.
|
|
Duration on respiratory support via endotracheal tube.
Tijdsspanne: The time until extubation will be censored at study completion, on average 30 days.
|
The hours between arrival of the intubated patient on the intensive care unit until extubation will be determined.
|
The time until extubation will be censored at study completion, on average 30 days.
|
|
Postoperative complications.
Tijdsspanne: All complications will be censored at study completion, on average 30 days.
|
Any complication that poses a risk for the patient occurring during the hospital stay and having been documented in the patient's file will be retrieved by carefully reviewing the files and recorded.
|
All complications will be censored at study completion, on average 30 days.
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Onderzoekers
- Hoofdonderzoeker: Martin Dworschak, MD, MBA, Medical University of Vienna
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Geschat)
1 oktober 2026
Primaire voltooiing (Geschat)
31 december 2028
Studie voltooiing (Geschat)
31 juli 2029
Studieregistratiedata
Eerst ingediend
4 april 2026
Eerst ingediend dat voldeed aan de QC-criteria
24 mei 2026
Eerst geplaatst (Werkelijk)
29 mei 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
29 mei 2026
Laatste update ingediend die voldeed aan QC-criteria
24 mei 2026
Laatst geverifieerd
1 april 2026
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- EK Nr: 1250/2021
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
NEE
Beschrijving IPD-plan
The primary reason for not sharing IPD is the protection of patient privacy.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .